Thomas Gad - Jan 18, 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
CHIEF BUSINESS OFFICER, Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Stock symbol
YMAB
Transactions as of
Jan 18, 2024
Transactions value $
$0
Form type
4
Date filed
1/22/2024, 05:52 PM
Previous filing
Dec 26, 2023
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +22.1K +15.73% $0.00 163K Jan 18, 2024 Direct F1
holding YMAB Common Stock 265K Jan 18, 2024 By GAD Enterprises LLC F2
holding YMAB Common Stock 60K Jan 18, 2024 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +133K $0.00 133K Jan 18, 2024 Common Stock 133K $9.83 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 22,100 restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 18, 2025, January 18, 2026 and January 18, 2027 subject to the continuing employment of the Reporting Person on each vesting date.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F4 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F5 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 18, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power Of Attorney